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Insulin Restores Metabolic Function in Cultured Cortical
Neurons Subjected to Oxidative Stress
Ana I. Duarte,1 Teresa Proenc¸a,2 Catarina R. Oliveira,3 Maria S. Santos,1 and A. Cristina Rego3
We previously demonstrated that insulin has a neuropro-
tective role against oxidative stress, a deleterious condi-
tion associated with diabetes, ischemia, and age-related
neurodegenerative diseases. In this study, we investigated
the effect of insulin on neuronal glucose uptake and me-
tabolism after oxidative stress in rat primary cortical
neurons. On oxidative stress, insulin stimulates neuronal
glucose uptake and subsequent metabolism into pyruvate,
restoring intracellular ATP and phosphocreatine. Insulin
also increases intracellular and decreases extracellular
adenosine, counteracting the effect of oxidative stress.
Insulin effects are apparently mediated by phosphatidyl-
inositol 3-K and extracellular signal–regulated kinase sig-
naling pathways. Extracellular adenosine under oxidative
stress is largely inhibited after blockade of ecto-5-nucle-
otidase, suggesting that extracellular adenosine results
preferentially from ATP release and catabolism. Moreover,
insulin appears to interfere with the ATP release induced
by oxidative stress, regulating extracellular adenosine lev-
els. In conclusion, insulin neuroprotection against oxida-
tive stress–mediated damage involves 1) stimulation of
glucose uptake and metabolism, increasing energy levels
and intracellular adenosine and, ultimately, uric acid for-
mation and 2) a decrease in extracellular adenosine, which
may reduce the facilitatory activity of adenosine receptors.
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Insulin is known to stimulate glucose uptake andintracellular metabolism in peripheral tissues. Al-though the role of insulin in the brain is less defined,it has been described to have neurotrophic, neuro-
modulator, and neuroendocrine effects (1). Transport of
insulin synthesized in pancreatic -cells into the brain can
occur indirectly, through a receptor-mediated process
across the blood-brain barrier, or directly via the area
postrema, a circumventricular region that lacks the blood-
brain barrier (2). Insulin can be also synthesized de novo
in the hippocampus, prefrontal cortex, enthorhinal cortex,
and olfactory bulb neurons (3). The presence of preproin-
sulin I and II mRNA and insulin receptor mRNA was
previously demonstrated in the brain (4). Insulin receptor
is highly expressed in neurons (5) in the olfactory bulb,
hypothalamus, cerebral cortex, and hippocampus (3).
The brain is one of the most metabolically active tissues,
relying on continuous glucose supply for synaptic trans-
mission and dendritic and axonal trafficking, thus helping
to maintain brain cognitive function (6,7). The main neu-
ronal glucose transporter, GLUT3, is highly expressed at
the neutrophil in regions of the central nervous system
(CNS) with high synaptic density and metabolic activity, at
the hippocampus and frontal and motor cortex (8). Inter-
estingly, evidence suggest that insulin influences cerebral
glucose metabolism at the entorhinal cortex and the
hippocampus (9).
The brain is continuously exposed to free radicals,
which may underlie the pathophysiology of neurodegen-
erative diseases, stroke, and diabetes complications affect-
ing the CNS (10,11). Lipid and protein oxidation alter the
conformation and structure of membrane proteins, includ-
ing GLUT3, thus decreasing neuronal glucose uptake and
intracellular ATP (12). In plasma from diabetic subjects
(13) and in brains of diabetic mice (14), high glucose levels
also produce permanent chemical alterations in proteins
and increase lipid peroxidation. Hyperglycemia associated
with stroke exacerbates ischemic brain damage in both
humans and animals (15,16). Under such conditions, brain
metabolism is affected (17), leading to lactate accumula-
tion and tissue acidosis (18), as well as mitochondrial
dysfunction and subsequent decrease in high-energy phos-
phates, ultimately resulting in oxidative stress and neuro-
nal death (18). Thus, the brain requires neuroendocrine
counterregulatory mechanisms to maintain blood glucose
within a narrow range.
We have previously demonstrated that oxidative stress
induces neuronal apoptosis and necrosis, as well as lipid
and protein oxidation, increasing the oxidation of GLUT3
by 4-hydroxynonenal (4-HNE) (19). Treatment with insulin
prevented oxidative stress and neuronal death by stimu-
lating uric acid levels and the glutathione redox cycle, in a
process mediated by phosphatidylinositol 3-kinase (PI-
3K)/Akt and extracellular signal–regulated kinase (ERK)
signaling pathways (19). The aim of the current work was
to investigate whether insulin neuroprotection during ox-
idative stress involved the restoration of neuronal glucose
energy metabolism. We demonstrate that insulin prevents
oxidative stress–induced impairment of glucose uptake
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and subsequent decrease in energy metabolism, thereby
regulating endogenous ATP and its hydrolysis to adenosine.
RESEARCH DESIGN AND METHODS
,-Methyleneadenosine-5-diphosphate (AMPCP) sodium salt, 2-deoxyglu-
cose (2-DG), ascorbic acid, DNase, FeSO4, insulin from porcine pancreas,
penicillin/streptomycin, S-(4-nitrobenzyl)-6-thioinosine (NBTI), soybean tryp-
sin inhibitor, and trypsin were purchased from Sigma (St. Louis, MO).
Neurobasal medium and B-27 supplement were from Gibco (Paisley, Scot-
land). 2-Deoxy-D-[1-3H]glucose (2-[3H]DG; 12.0 Ci/mmol) was from Amersham
International (Little Chalfont, U.K.). Scintillation Universol cocktail was from
ICN (Irvine, CA). PD98059 was from Calbiochem (Darmstadt, Germany).
Lichrospher 100 RP-18 (5 m) high-performance liquid chromatography
column was from Merck (Darmstadt, Germany). Wortmannin and LY294002
were kindly provided by Alomone Labs (Jerusalem, Israel). All other reagents
were of the highest grade of purity commercially available.
Culture of cortical neurons. Pregnant female Wistar rats were obtained
from our local colony (Animal Facilities, Faculty of Medicine, University of
Coimbra). Animals were kept under controlled light and humidity conditions.
Cortical neurons were isolated from brains of 15- to 16-day-old Wistar rat
embryos, using a previously described procedure (19,20). Adhering to proce-
dures approved by the institutional animal care and use committee, pregnant
rat females were killed by cervical displacement and decapitation. The brain
cortices were removed from embryos and placed in sterile Krebs medium
containing (in mmol/l): 120.9 NaCl, 4.8 KCl, 1.22 KH2PO4, 25.5 NaHCO3, 13.0
glucose, and 10.0 HEPES, pH 7.4, supplemented with 0.3% BSA, 0.05% trypsin,
and 0.04 mg/ml DNase for 10 min at 37°C. The reaction was stopped by
addition of Krebs medium (1:1 dilution) containing 0.075% soybean trypsin
inhibitor and 0.04 mg/ml DNase. The supernatant was discarded after centrif-
ugation at 1,000g for 5 min in a Sigma 3K10 centrifuge, and the cells were
dissociated in new Krebs medium. The neurons were resuspended in neuro-
basal medium supplemented with 2% B-27, 0.2 mmol/l glutamine, 100 units/ml
penicillin, and 0.1 mg/ml streptomycin, and then they were cultured for 6 days
in 95% air/5% CO2 at 37°C. Cortical neurons were plated at different densities
on poly-L-lysine (0.1 mg/ml)–covered plates: 0.16  106 cells/cm2 for measure-
ment of 2-[3H]DG; uptake or 0.26  106 cells/cm2 for analysis of pyruvate,
lactate, adenine nucleotides, and adenosine. Previous studies in our labora-
tory showed that cortical cultures contained few glial cells (10%), as
assessed by immunocytofluorescence using anti-MAP2 (microtubule-associ-
ated protein) and anti-GFAP (glial fibrillary acidic protein) (S. Almeida and
A.C.R., unpublished observations).
Incubation with insulin and induction of oxidative stress. By following
previously established experimental conditions (19), 0.1 or 10 mol/l insulin
was added to neurobasal medium at 48 h (at 4 days in vitro, renewed every
24 h) or immediately (at 6 days in vitro) before induction of oxidative stress
with 1.5 mmol/l ascorbic acid and 7.5 mol/l FeSO4 for 15 min at 37°C in
sodium saline solution containing (in mmol/l): 132.0 NaCl, 4.0 KCl, 1.2
Na2HPO4, 1.4 MgCl2, 1.0 CaCl2, 6.0 glucose, and 10.0 HEPES, pH 7.4. The cells
were further incubated for 5 h in neurobasal medium in the absence of the
oxidizing agents. Insulin was present throughout the experiments. To analyze
the involvement of insulin receptor–mediated signaling pathways, the neurons
were incubated with 50 nmol/l Wortmannin, 5 mol/l LY294002 (inhibitors of
PI-3K/Akt pathway), or 30 mol/l PD98059 (an inhibitor of ERK pathway) 30
min before insulin incubation and maintained throughout the experiments.
When present, 1 mol/l NBTI (an inhibitor of adenosine transporter) or 50
mol/l AMPCP (an inhibitor of ecto-5-nucleotidase) were incubated with the
neurons for 5 min before insulin and maintained throughout the experiments.
Analysis of 2-[3H]DG uptake. Glucose accumulation was analyzed by
measuring the uptake of 1 Ci/ml (12.0 Ci/mmol) of 2-[3H]DG, a nonmetabo-
lizable analog of glucose, according to a method described elsewhere (6).
After incubation, the neurons were washed with sodium saline solution
containing 6 mmol/l glucose, then washed with glucose-free sodium solution,
and further incubated with glucose-free solution containing 2-[3H]DG (1
Ci/ml) and nontritiated 2-DG (1 mmol/l) at 37°C. 2-[3H]DG uptake was
stopped at 10 min by rinsing the cells with ice-cold sodium solution. All
experiments were performed in the absence of glucose. After solubilization
with 1 mol/l NaOH at 4°C, the radioactivity was counted in a Packard Tri-Carb
2500 TR liquid scintillation analyzer. Results were expressed as nanomoles of
2-[3H]DG uptake per 106 cells.
Assessment of intracellular pyruvate and lactate. Neurons were washed
with PBS (0–4°C), scrapped, and extracted with 0.6 mol/l perchloric acid
supplemented with 25 mmol/l EDTA-Na. Cell extracts were centrifuged at
14,000g for 2 min in an Eppendorf Centrifuge 5415C at 4°C to remove cell
debris. Lactate and pyruvate were determined in the supernatant by using kits
from Randox Laboratories (Antrim, U.K.) and Ben SRL (Milan, Italy), respec-
tively. Results were expressed in percent of control (with 0.14 considered as
100%) in the absence of insulin and ascorbate/Fe2.
Measurement of adenine nucleotides, phosphocreatine, and adenosine.
Neurons were extracted with 0.6 mol/l perchloric acid, supplemented with 25
mmol/l EDTA-Na, and centrifuged at 14,000g for 2 min at 4°C in an
Eppendorf 5415C centrifuge, according to previously described methods, with
some modifications (21). The resulting pellet was solubilized with 1 mol/l
NaOH for total protein analysis by the Sedmak method (22). After neutraliza-
tion with 3 mol/l KOH in 1.5 mol/l Tris, the samples were centrifuged at
14,000g for 2 min (0–4°C). The resulting supernatants were assayed for ATP,
ADP, and AMP or adenosine by separation in a reverse-phase high-perfor-
mance liquid chromatograph, with detection at 254 nm. These samples were
also used to determine intracellular phosphocreatine, at 340 nm, according to
a previously described method (23). To determine extracellular accumulation
of adenine nucleotides or adenosine, neurobasal medium was recovered and
prepared using a similar procedure. Because measurable levels of extracellu-
lar adenosine were detected, experiments were performed without adenosine
deaminase inhibitor. Results were expressed in percent of control, in the
absence of insulin and ascorbate/Fe2, considering 2.1, 0.3, 0.9, and 6.3
nmol/mg protein as 100% for intracellular ATP, ADP, AMP, and adenosine,
respectively; 2.6, 2.3, and 7.4 pmol/mg protein as 100% for extracellular ATP,
ADP, and AMP, respectively; and 1.8 nmol/mg protein as 100% for extracellular
adenosine.
Data analysis and statistics. Results are the means  SEM of the indicated
number of independent experiments, run in duplicate or triplicate. Statistical
significance was analyzed using the one-way ANOVA for multiple compari-
sons, with the Bonferroni post test. A P value 0.05 was considered
significant.
RESULTS
Insulin stimulates glucose uptake and pyruvate/lac-
tate formation on oxidizing conditions. Previously, we
showed that insulin prevents ascorbate/Fe2-induced neu-
ronal death (19). Neuroprotective effects of insulin were
analyzed after incubation for 48 h (0.1 mol/l insulin) or
immediately before (10 mol/l insulin) exposure to ascor-
bate/Fe2, under experimental conditions characterized
by no significant changes induced by insulin alone (19).
Insulin also prevented oxidation of GLUT3 by 4-HNE (19),
strongly suggesting changes in neuronal glucose accumu-
lation, the main brain metabolic substrate. Under physio-
logical conditions, glucose is metabolized to pyruvate via
glycolysis. A minor proportion of lactate can also result
from the reduction of pyruvate.
In this study, we analyzed the effect of insulin on
glucose transport, by measuring 2-[3H]DG uptake. 2-DG is
a synthetic glucose analog phosphorylated to 2-deoxy-D-
glucose-6-phosphate by hexokinase. Ascorbate/Fe2-in-
duced oxidative stress (1.9  0.6 nmol thiobarbituric acid
reactive substances/mg protein) (19) caused a decrease in
neuronal 2-[3H]DG uptake by 	57% (Fig. 1A). This de-
crease was completely prevented by 0.1 and 10 mol/l
insulin. Insulin per se did not significantly affect 2-[3H]DG
uptake (Fig. 1A).
Because these results suggested that glycolysis was
stimulated by insulin, we determined the endogenous
levels of pyruvate and lactate, two end products of glyco-
lysis (Fig. 1B). Although insulin per se did not affect
pyruvate/lactate levels, it completely prevented the de-
crease in pyruvate/lactate induced by oxidative stress (Fig.
1B) by increasing pyruvate formation (data not shown).
Insulin-mediated recovery of neuronal 2-[3H]DG uptake
and pyruvate/lactate after oxidative stress highly suggest
the stimulation of the glycolytic pathway.
Insulin restores intra- and extracellular adenine nu-
cleotides on oxidative stress. One of the main conse-
quences of insulin-mediated metabolic stimulation
observed in Fig. 1 is the increase in high-energy com-
pounds, namely ATP and phosphocreatine; the latter con-
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stitutes a reservoir for rapid ATP regeneration. Thus, we
determined the effect of insulin and insulin receptor–
mediated signaling pathways on intracellular ATP, ADP,
AMP, and phosphocreatine levels (Tables 1 and 2). Oxida-
tive stress significantly decreased intracellular ATP by
	44%, which was completely prevented by 0.1 or 10 mol/l
insulin (Table 1). Insulin per se did not significantly affect
these parameters. Although oxidative stress did not mod-
ify intracellular ADP, ascorbate/Fe2 plus insulin de-
creased ADP levels by 41%, following the rise in
intracellular ATP (Table 1). Thus, under oxidized condi-
tions the ATP-to-ADP ratio was largely restored by insulin.
Additionally, insulin (0.1 and 10 mol/l) almost completely
regenerated the ascorbate/Fe2-induced decrease in intra-
cellular phosphocreatine (Table 2). A decrease in phos-
phocreatine/creatine and an increase in lactate/pyruvate
may constitute early signs of mitochondrial defect (24).
Moreover, uncoupling of oxidative phosphorylation was
associated with a decrease in ATP and phosphocreatine on
kainate injection in rat brain (25).
Pretreatment with the PI 3-K inhibitors wortmannin (50
nmol/l) or LY294002 (5 mol/l) and the mitogen-activated
protein kinase (MEK) inhibitor PD98059 (30 mol/l) sig-
nificantly decreased intracellular ATP and the ATP-to-ADP
ratio under control and oxidized conditions, and it in-
creased intracellular ADP under control conditions (Table
1). Nevertheless, insulin was unable to rescue oxidative
stress–mediated changes in intracellular ATP or ADP in
the presence of the inhibitors of PI 3-K or MEK (Table 1),
suggesting that insulin-induced recovery of intraneuronal
FIG. 1. Insulin prevents impairment of glucose metabolism under
oxidative stress. Glucose metabolism was evaluated by determining
glucose accumulation, using 2-[3H]-deoxyglucose uptake (A) and intra-
cellular pyruvate/lactate (B). Data are the means  SE of five (A) or
eight (B) experiments. *P < 0.05 vs. control; £P < 0.05, ££P < 0.01,
£££P < 0.001 vs. ascorbate/Fe2 without insulin. , control; f,
ascorbate/Fe2.
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ATP from ADP under oxidative stress may involve both PI
3-K and MEK signaling pathways.
The effect of insulin on intracellular AMP was also
analyzed (Table 1). Insulin restored the decrease in intra-
cellular AMP on oxidation. Treatment with wortmannin,
LY294002, or PD98059 increased intracellular AMP per se
(Table 1). However, neither ascorbate/Fe2 nor insulin
significantly affected intracellular AMP in the presence of
PI 3-K and MEK inhibitors (Table 1).
To further explain insulin-induced changes in intracel-
lular adenine nucleotides, namely ATP, in oxidized neu-
rons, we examined the levels of extracellular ATP, ADP,
and AMP. Ascorbate/Fe2-induced increase in extracellu-
lar ATP was completely abolished by insulin (Table 3).
Conversely, insulin prevented the decrease (by 	26%) in
extracellular ADP induced by oxidative stress (Table 3).
Neither ascorbate/Fe2 nor insulin significantly affected
extracellular accumulation of AMP (Table 3).
These data suggest that decreased intracellular ATP
after oxidative stress was caused by inhibition of glucose
metabolism and increased extracellular ATP. Further-
more, insulin-induced recovery of intracellular ATP from
ADP on oxidative stress resulted from 1) stimulation of
glucose accumulation and metabolism through glycolysis
and possibly oxidative phosphorylation and/or at the ex-
pense of phosphocreatine for rapid ATP regeneration
and/or 2) blockade of ATP release.
Insulin modifies intra- and extracellular levels of
adenosine on oxidative stress. On oxidative stress,
reduction of intracellular ATP was followed by a decre-
ment in AMP, both of which were prevented by insulin.
Adenosine resulting from the catabolism of purines may
constitute a very sensitive signal of increased metabolic
rate or metabolic stress. Moreover, subsequent adenosine
catabolism results in uric acid, an important neuronal
antioxidant. Extracellularly, adenosine modulates the ac-
tivity of inhibitory A1 and A3 receptors, or facilitatory A2A
and A2B receptors (26), which mediate cell survival or cell
death, respectively. Taking into account the dual role of
adenosine in neuronal degeneration, we further explored
the effect of insulin on intra- and extracellular adenosine
in neurons subjected to oxidative stress. To our knowl-
edge, this is the first report that evaluates the effect of
insulin on adenosine levels.
Similarly to ATP and AMP (Table 1), ascorbate/Fe2-
induced decrease in intracellular adenosine (	51%) was
significantly prevented by insulin (Fig. 2A). Pretreatment
with the PI 3-K inhibitors wortmannin (Fig. 2B) or
LY294002 (Fig. 2C) and the MEK inhibitor PD98059 (Fig.
2D), per se, significantly decreased intracellular adeno-
sine. Nevertheless, insulin did not rescue the decrease in
intracellular adenosine induced by oxidative stress in the
presence of inhibitors of PI 3-K (Fig. 2B and C) or MEK
(Fig. 2D). Moreover, insulin differently affected the extra-
cellular accumulation of adenosine (Fig. 3A and B). Ascor-
bate/Fe2-induced increase in extracellular adenosine
(	51%) was only significantly attenuated by 10 mol/l
insulin, whereas 0.1 mol/l insulin completely decreased
extracellular adenosine (data not shown).
Because extracellular adenosine can result either from
intracellular AMP degradation and subsequent release via
bidirectional adenosine transporters or from extracellular
catabolism of released nucleotides, catalyzed by ecto-
nucleotidases (27), we also analyzed the origin of extra-
cellular adenosine. Cortical neurons were pretreated with
inhibitors of adenosine transporter (NBTI) and ecto-5-
nucleotidase (AMPCP), which were previously shown to
prevent the increase in extracellular adenosine induced by
oxidative stress (21,28).
NBTI (1 mol/l) per se did not significantly affect
intracellular adenosine (Fig. 2E compared with Fig. 2A),
but it increased extracellular adenosine by	29% (Fig. 3A),
demonstrating the role of this transporter under control
conditions. On oxidative stress in the presence of NBTI,
intracellular adenosine increased by 	26% (Fig. 2E com-
pared with Fig. 2A), whereas extracellular adenosine
decreased by 	13% (Fig. 3A) compared with ascorbate/
Fe2 alone. These data suggest that the nucleoside trans-
porter partially contributed to the increase in extracellular
adenosine under oxidative stress. Treatment of oxidized
neurons with NBTI plus insulin (10 mol/l) completely
restored intra- and extracellular adenosine (Figs. 2E and
3A).
To analyze the contribution of the catabolism of re-
leased ATP to extracellular adenosine, cortical neurons
were pretreated with AMPCP, which blocks the hydrolysis
of 5-AMP into adenosine (29). AMPCP (50 mol/l) per se
reduced extracellular adenosine by 	25% (Fig. 3B). Incu-
bation with AMPCP under oxidative stress conditions
largely decreased extracellular adenosine (	91%) com-
pared with ascorbate/Fe2 alone, suggesting that this
pathway highly contributes to the increase in extracellular
adenosine. On oxidative stress, insulin (10 mol/l) plus
AMPCP decreased (by 	19% compared with ascorbate/
Fe2 plus insulin) extracellular adenosine accumulation to
TABLE 2
Insulin restores intracellular phosphocreatine on oxidative stress
No insulin
0.1 mol/l
insulin
10 mol/l
insulin
Control (pmol/mg
protein) 9.19 0.88 7.97 0.75 8.65 0.76
Asc/Fe2 (pmol/mg
protein) 5.27 0.47* 7.56 0.6† 8.07 0.74†
Data are means  SE of six experiments. Neurons were incubated
with insulin before ascorbate/Fe2 treatment. Intracellular phospho-
creatine was determined as described in RESEARCH DESIGN AND METHODS.
*P  0.01 vs. control; †P  0.05 vs. ascorbate/Fe2 without insulin.
TABLE 3
Insulin affects extracellular adenine nucleotides under oxidative
stress
Control Asc/Fe2
No insulin (% of control)
ATPext 100.0 5 135.3 10.2*
ADPext 100.0 1.1 73.6 5.1*
AMPext 100.0 8.7 105.7 8.1
0.1 mol/l insulin (% of control)
ATPext 90.7 6.7 90.8  8.5†
ADPext 103.6 8.8 104.4 6.1†
AMPext 100.3 14.0 102.5 8.6
10 mol/l insulin (% of control)
ATPext 92.6 8.8 88.6  5.3‡
ADPext 96.9 9.3 110.8 8.3‡
AMPext 102.5 8.1 97.6 9.6
Data are means  SE of six experiments. Neurons were incubated
with insulin before ascorbate/Fe2 treatment. Intracellular ATP,
ADP, and AMP were determined by reverse-phase high-performance
liquid chromatography. *P 0.05 vs. control; †P 0.05, ‡P 0.01 vs.
ascorbate/Fe2 without insulin.
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the same extent as the decrease observed in the presence
of NBTI.
Thus, similar to intracellular adenine nucleotides, PI 3-K
and ERK signaling pathways appear to be involved in the
regulation of intracellular adenosine by insulin. Further-
more, blockade of ectonucleotidases largely inhibited ex-
tracellular adenosine accumulation under oxidized
conditions, suggesting that extracellular adenosine occurs
mainly through the release of adenine nucleotides to the
extracellular space and their rapid degradation into aden-
osine, as described previously (21,28). However, we can-
not exclude a contribution of the reversal of adenosine
transport under these conditions.
Insulin partially prevented extracellular adenosine accu-
mulation in oxidized neurons mainly by interfering with
the release of ATP, limiting its subsequent metabolization
into adenosine. This can be explained by two observa-
tions: 1) insulin plus NBTI produced an additive effect,
suggesting the occurrence of two independent mecha-
nisms, and 2) AMPCP slightly influenced the decrease in
extracellular adenosine caused by insulin under oxidative
stress, suggesting that it occurred, at least partially, inde-
pendently of ecto-5-nucleotidase inhibition. Thus, reduc-
tion of extracellular adenosine most likely occurred
because of the inhibition of adenine nucleotide (ATP)
release, preceding ecto-5-nucleotidase.
DISCUSSION
In the current study, we demonstrate that insulin protects
cortical neurons against oxidative stress–induced impair-
ment of glucose accumulation and metabolism through the
stimulation of glycolysis and high-phosphate metabolism,
including phosphocreatine and ATP generation. This sup-
ports the replenishment of intracellular adenosine, which
can be metabolized to uric acid, as we have previously
observed (19). Moreover, the neuroprotective role of insu-
lin in oxidative stress may involve the inhibition of ATP
release and its subsequent extracellular metabolization,
restoring the levels of extracellular adenosine. Further-
more, activation of PI 3-K/Akt and ERK signaling pathways
appears to mediate the neuroprotective role of insulin
against metabolic impairment under oxidative stress.
Thus, the current results are complementary to those
previously observed in primary cortical neurons regarding
insulin neuroprotection against oxidative stress (19).
It has been widely demonstrated that neuronal and
synaptosomal treatment with FeSO4 inhibits the glucose
transporter either directly, by 4-HNE– or acrolein-induced
oxidation of GLUT3, or indirectly via lipid peroxidation
(30,31). Glucose transport inhibition can also result from
oxidative stress–mediated decrease in endogenous gluta-
thione (19,32). We previously observed the formation of
4-HNE adducts on GLUT3 in ascorbate/Fe2-treated corti-
cal neurons (19), supporting GLUT3 inhibition and the
subsequent impairment of neuronal glucose uptake and
metabolism.
Changes in phosphocreatine and pyruvate/lactate levels
may constitute one of the early signs of mitochondrial
respiratory chain dysfunction (24). In this regard, the
observed decrease in pyruvate/lactate and phosphocre-
FIG. 2. Insulin-mediated changes in intracellular adenosine on oxidative stress. Neurons were preincubated in the absence (A) or in the presence
of 50 nmol/l wortmannin (B), 5 mol/l LY294002 (C), 30 mol/l PD98059 (D), or 1 mol/l NBTI (E). Adenosine was determined by reverse-phase
high-performance liquid chromatography. Data are the means SE of six experiments. ***P< 0.001 vs. control without insulin; £P< 0.05, ££P<
0.01, £££P < 0.001 vs. ascorbate/Fe2 without insulin. , no insulin; f, 0.1 mol/l insulin; o, 10 mol/l insulin. Asc, ascorbate.
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atine suggest that oxidative stress affects both glycolysis
and oxidative metabolism. ATP depletion may exacerbate
free radical generation, culminating in neuronal death
(19,33). A decrease in intracellular ATP under oxidative
stress may also result from its release and subsequent
extracellular metabolization to adenosine by ectonucleoti-
dases. These results are in agreement with our previous
data obtained in cultured retinal neurons exposed to
ascorbate/Fe2 (21,28) and with an increase in ecto-5-
nucleotidase activity observed after oxidation of brain
membranes (34). However, we cannot exclude the contri-
bution of reversal of the nucleoside transporter.
Despite some controversy regarding the role of extra-
cellular adenosine, the type of receptor activated after
oxidation appears to be determined by its origin; adeno-
sine resulting from extracellular degradation of AMP pref-
erentially activates facilitatory A2A receptors (27), whereas
adenosine resulting from the reversal of nucleoside trans-
porter activates both inhibitory A1 (28,35) and facilitatory
A2A receptors (28). Under our experimental conditions,
neuronal oxidation caused ATP release and its subsequent
catabolism into extracellular adenosine, which can acti-
vate facilitatory adenosine receptors, leading to neuronal
death. Nevertheless, oxidative stress was previously
shown to decrease ligand binding to synaptosomal A1 (36)
and striatal membrane A2A receptors (37), emphasizing the
dual role of adenosine upon oxidation. We also show that
oxidative stress decreases intracellular ATP production,
which is metabolized into adenosine, ultimately decreas-
ing the levels of uric acid (19), an important endogenous
antioxidant. These data suggest that increased extracellu-
lar adenosine and decreased intracellular adenosine con-
tribute to neurodegeneration on oxidative stress.
There is some controversy regarding the role of insulin
in brain glucose transport. Seaquist et al. (38) hypothe-
sized that glucose uptake and metabolism in the human
brain was insulin independent. However, Prasannan (39)
and Bingham et al. (40) showed that insulin stimulated
glucose uptake and metabolism in rat brain cortical slices
and in human brain cortex. These authors hypothesized
that GLUT3 mediated glucose uptake evoked by insulin.
Accordingly, insulin resistance may also affect GLUT3
activity (41). In this regard, insulin-mediated stimulation of
glucose uptake on oxidative stress correlates with the
observation of decreased GLUT3 oxidation by 4-HNE,
most likely resulting from the stimulation of endogenous
antioxidant defenses (19). Alternatively, insulin-induced
regulation of glucose uptake may involve the activation of
phospholipase C
 and protein kinase C, leading to phos-
phorylation of glucose transporters (42). Nevertheless,
insulin could not rescue serum-free treated cultured neu-
rons from decreased glucose uptake (43), suggesting that
insulin neuroprotection may involve mechanisms other
than the regulation of glucose transport/metabolism.
It is widely accepted that the major rate-limiting step in
neuronal glucose metabolism is its phosphorylation by
hexokinase, the first ATP-driven reaction of glycolysis
(44). Insulin appears to upregulate hexokinase activity,
localization, and expression, thus modulating glucose me-
tabolism to meet the energy demands of sensory neurons
(45). In this regard, insulin-induced increases in intracel-
lular pyruvate/lactate, phosphocreatine, and ATP-to-ADP
ratio on oxidative stress support the hypothesis that,
similar to nonneuronal tissues (3), the peptide stimulates
neuronal glycolysis and oxidative metabolism and/or the
rapid phosphorylation of ADP into ATP at the expense of
phosphocreatine, implicating creatine kinase activation.
Brain insulin infusion was previously shown to have an
anabolic effect on energy metabolism in the hippocampus,
increasing phosphocreatine (46), whereas neuronal insulin
receptor inhibition led to severe abnormalities in energy
metabolism (3). Metabolic effects of insulin appear to
depend on the activation of PI 3-K and/or ERK signaling
pathways. In agreement, insulin stimulation of mitochon-
drial function involved the activation of PI 3-K signaling
pathways in cultured adult sensory neurons (45). Further-
more, insulin can modulate hippocampal synaptic plastic-
ity through the activation of N-methyl-D-aspartate
receptors, a subtype of glutamate receptors, and the PI 3-K
pathway (47).
In this study, we clearly show that insulin prevents a
decrease in intracellular adenosine and an increase in
extracellular adenosine evoked by oxidative stress. Con-
cordant with changes in adenine nucleotides, alterations
in intracellular adenosine evoked by insulin seemed to
depend on the activation of PI 3-K and ERK signaling
pathways. Hence, the insulin signaling cascade may pro-
tect neurons against oxidative stress either by stimulating
intracellular ATP metabolism to adenosine (Fig. 4) and
uric acid (19), thus contributing to the replenishment of
intracellular antioxidant defenses, and/or by interfering
with ATP release and extracellular degradation into aden-
osine, decreasing the extracellular adenosine pool (Fig. 4).
Insulin protection, determined by a decrease in apoptotic
and necrotic neuronal death (19), appears to involve a
FIG. 3. Regulation of extracellular adenosine induced by insulin on
oxidative stress. Neurons were preincubated with 1 mol/l NBTI (A) or
50 mol/l AMPCP (B). Data are the means  SE of six experiments.
*P < 0.05, **P < 0.01 vs. control (not treated with inhibitors or
insulin); £P < 0.05 vs. ascorbate/Fe2 without insulin; P < 0.05 vs.
ascorbate/Fe2 in the presence of insulin. , control; f, ascorbate/
Fe2; u, NBTI (A) or AMPCP (B); o, NBTI plus ascorbate/Fe2 (A) or
AMPCP plus ascorbate/Fe2 (B).
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decrease in extracellular adenosine, possibly protecting
against facilitatory adenosine receptor activation.
After transient global ischemia in CNS parenchyma,
insulin administration was shown to prevent neuronal
damage and necrosis via activation of insulin receptor and
IGF-1 receptor but independently of its effect on glucose
levels (48). However, in focal ischemia, insulin protection
depended on the regulation of blood glucose levels (49).
Under such conditions, insulin infusion combined with
glucose may stimulate glucose uptake and glycolysis,
producing anaerobic ATP. This would limit the decrease in
tissue high-energy phosphates and the increase in free
radicals occurring in ischemia (18,50). By showing that
insulin prevents neuronal apoptosis and necrosis (19) and
restores neuronal glucose metabolism, modulating the
extracellular adenosine pool through the activation of
intracellular signaling pathways, we provide important
evidence toward the potential therapeutic use of insulin
against neuronal dysfunction in strokes. However, when
considering insulin therapy for the treatment of stroke,
blood glucose levels should be maintained in the normal
range to avoid biochemical and neuropathological conse-
quences of hyperinsulinemia-induced severe hypoglyce-
mia in the brain (49).
ACKNOWLEDGMENTS
This work was supported by the Fundac¸a˜o para a Cieˆncia
e a Tecnologia (FCT) (POCTI/ESP/43642/1999 and POCI/
SAU-NEU/57310/2004). A.I.D. is a recipient of a fellowship
from FCT (SFRH/BD/5338/2001).
We thank Prof. Paulo Santos (Center for Neuroscience
and Cell Biology, University of Coimbra, Portugal) for
kindly providing NBTI. We also thank Prof. Milton Costa
(Center for Neuroscience and Cell Biology, University of
Coimbra, Portugal) for critical reading of the manuscript.
REFERENCES
1. Gerozissis K: Brain insulin and feeding: a bi-directional communication.
Eur J Pharmacol 490:59–70, 2004
2. Sankar R, Thamotharan S, Shin D, Moley KH, Devaskar SU: Insulin-
responsive glucose transporters-GLUT8 and GLUT4 are expressed in the
developing mammalian brain. Brain Res Mol Brain Res 107:157–165, 2002
3. Hoyer S: Glucose metabolism and insulin receptor signal transduction in
Alzheimer disease. Eur J Pharmacol 490:115–125, 2004
4. Schechter R, Beju D, Gaffney T, Schaefer F, Whetsell L: Preproinsulin I and
II mRNAs and insulin electron microscopic immunoreaction are present
within the rat fetal nervous system. Brain Res 736:16–27, 1996
5. Gerozissis K: Brain insulin: regulation, mechanisms of action and func-
tions. Cell Mol Neurobiol 23:1–25, 2003
6. Pellerin L, Magistretti PJ: Glutamate uptake into astrocytes stimulates
aerobic glycolysis: a mechanism coupling neuronal activity to glucose
utilization. Proc Natl Acad Sci U S A 91:10625–10629, 1994
7. Vannucci SJ, Maher F, Simpson IA: Glucose transporter proteins in brain:
delivery of glucose to neurons and glia. Glia 21:2–21, 1997
8. Choeiri C, Staines W, Messier C: Immunohistochemical localization and
quantification of glucose transporters in the mouse brain. Neuroscience
111:19–34, 2002
9. Stockhorst U, de Fries D, Steingrueber HJ, Scherbaumb WA: Insulin and
the CNS: effects on food intake, memory, and endocrine parameters and
the role of intranasal insulin administration in humans. Physiol Behav
83:47–54, 2004
10. Kokoszka JE, Coskun P, Esposito LA, Wallace DC: Increased mitochon-
drial oxidative stress in the Sod2 (/-) mouse results in the age-related
decline of mitochondrial function culminating in increased apoptosis. Proc
Natl Acad Sci U S A 98:2278–2283, 2001
11. Chong ZZ, Li F, Maiese K: Oxidative stress in the brain: novel cellular
targets that govern survival during neurodegenerative disease. Prog Neu-
robiol 75:207–246, 2005
12. Butterfield AD, Castegna A, Lauderback CM, Drake J: Evidence that
amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alz-
heimer’s disease brain contribute to neuronal death. Neurobiol Aging
23:655–664, 2002
13. Rabini RA, Tesei M, Galeazzi T, Dousset N, Ferretti G, Mazzanti L:
Increased susceptibility to peroxidation of VLDL from non-insulin-depen-
dent diabetic patients: a possible correlation with fatty acid composition.
Mol Cell Biochem 199:63–67, 1999
14. Makar TK, Hungund BL, Cook GA, Kashfi K, Cooper AJ: Lipid metabolism
and membrane composition are altered in the brains of type II diabetic
mice. J Neurochem 64:2159–2168, 1995
15. de Courten-Myers GM, Kleinholz M, Wagner KR, Myers RE: Fatal strokes in
hyperglycemic cats. Stroke 20:1707–1715, 1989
16. Yip PK, He YY, Hsu CY, Garg N, Marangos P, Hogan EL: Effect of plasma
glucose on infarct size in focal cerebral ischemia-reperfusion. Neurology
41:899–905, 1991
17. Voll CL, Auer RN: The effect of postischemic blood glucose levels on
ischemic brain damage in the rat. Ann Neurol 24:638–646, 1988
18. Garg R, Chaudhuri A, Munschauer F, Dandona P: Hyperglycemia, insulin,
and acute ischemic stroke: a mechanistic justification for a trial of insulin
infusion therapy. Stroke 37:267–273, 2006
19. Duarte AI, Santos MS, Oliveira CR, Rego AC: Insulin neuroprotection
against oxidative stress in cortical neurons: involvement of uric acid and
glutathione antioxidant defenses. Free Radic Biol Med 39:876–889, 2005
20. Almeida S, Domingues A, Rodrigues L, Oliveira CR, Rego AC: FK506
prevents mitochondrial-dependent apoptotic cell death induced by 3-nitro-
FIG. 4. Stimulation of glucose metabolism and de-
creased extracellular adenosine mediate insulin
neuroprotection against oxidative stress. After
ascorbate/Fe2 treatment, insulin-induced activa-
tion of PI 3-K and ERK signaling pathways stimu-
lates neuronal glucose uptake and glycolysis,
increasing intracellular ATP-to-ADP ratio, phos-
phocreatine (PCr), and adenosine (ADO). As a
consequence, uric acid levels are increased, which,
together with the increase in reduced glutathione
(GSH)/oxidized glutathione (GSSH), help to coun-
terbalance oxidative stress. Insulin also interferes
with ATP release, regulating its metabolization to
extracellular adenosine under oxidized conditions.
Pyr, pyruvate; Lac, lactate.
A.I. DUARTE AND ASSOCIATES
DIABETES, VOL. 55, OCTOBER 2006 2869
propionic acid in rat primary cortical cultures. Neurobiol Dis 17:435–444,
2004
21. Rego AC, Santos MS, Oliveira CR: Adenosine triphosphate degradation
products after oxidative stress and metabolic dysfunction in cultured
retinal cells. J Neurochem 69:1228–1235, 1997
22. Sedmak JJ, Grossberg FE: A rapid, sensitive and versatile assay for protein
using coomassie brilliant blue G250. Anal Biochem 79:544–552, 1977
23. Heinz F, Weier H: Creatine phosphate. In Methods of Enzymatic Analy-
sis. 3rd ed. Bergmeyer HU, Bergmeyer J, Gral M, Eds. VCH, 1985, p.
507–514
24. Erecinska M, Nelson D: Effects of 3-nitropropionic acid on synaptosomal
energy and transmitter metabolism: relevance to neurodegenerative brain
diseases. J Neurochem 63:1033–1041, 1994
25. Gupta RC, Dettbarn WD: Prevention of kainic acid seizures-induced
changes in levels of nitric oxide and high-energy phosphates by 7-nitro-
indazole in rat brain regions. Brain Res 981:184–192, 2003
26. Schulte G, Fredholm BB: Signalling from adenosine receptors to mitogen-
activated protein kinases. Cell Signal 15:813–827, 2003
27. Cunha RA: Adenosine as a neuromodulator and as a homeostatic regulator
in the nervous system: different roles, different sources and different
receptors. Neurochem Int 38:107–125, 2001
28. Agostinho P, Caseiro P, Rego AC, Duarte EP, Cunha RA, Oliveira CR:
Adenosine modulation of D-[3H]aspartate release in cultured retina cells
exposed to oxidative stress. Neurochem Int 36:255–265, 2000
29. Cunha RA, Sebastia˜o AM, Ribeiro JA: Ecto-5-nucleotidase is associated
with cholinergic nerve terminals in the hippocampus but not in the
cerebral cortex of the rat. J Neurochem 59:657–666, 1992
30. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP: Amyloid beta-peptide
impairs glucose transport in hippocampal and cortical neurons: involve-
ment of membrane lipid peroxidation. J Neurosci 17:1046–1054, 1997
31. Lovell MA, Xie C, Markesbery WR: Acrolein, a product of lipid peroxida-
tion, inhibits glucose and glutamate uptake in primary neuronal cultures.
Free Rad Biol Med 29:714–720, 2000
32. Maddux BA, See W, Lawrence JC Jr, Goldfine AL, Goldfine ID, Evans JL:
Protection against oxidative stress-induced insulin resistance in rat L6
muscle cells by micromolar concentrations of -lipoic acid. Diabetes
50:404–410, 2001
33. Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-
Daouk R, Beal MF: Neuroprotective effects of creatine and cyclocreatine in
animal models of Huntington’s disease. J Neurosci 18:156–163, 1998
34. Mishra OP, Delivoria-Papadopoulos M, Cahillane G, Wagerle LC: Lipid
peroxidation as the mechanism of modification of brain 5-nucleotidase
activity in vitro. Neurochem Res 15:237–242, 1990
35. Almeida CG, Mendonc¸a A, Cunha RA, Ribeiro JA: Adenosine promotes
neuronal recovery from reactive oxygen species induced lesion in rat
hippocampal slices. Neurosci Lett 339:127–130, 2003
36. Oliveira JC, Constantino MD, Sebastia˜o AM, Ribeiro JA: Ascorbate/Fe3-
induced peroxidation and inhibition of the binding of A1 adenosine
receptor ligands in rat brain membranes. J Neurochem Int 26:263–268,
1995
37. Alfaro TM, Vigia E, Oliveira CR, Cunha RA: Effect of free radicals on
adenosine A2A and dopamine D2 receptors in the striatum of young adult
and aged rats. Neurochem Int 45:733–738, 2004
38. Seaquist ER, Damberg GS, Tkac I, Gruetter R: The effect of insulin on in
vivo cerebral glucose concentrations and rates of glucose transport/
metabolism in humans. Diabetes 50:2203–2209, 2001
39. Prasannan KG: Effect of insulin on glucose metabolism in cerebral cortex
slices under aerobic and anaerobic conditions. J Neurochem 19:1825–1828,
1972
40. Bingham EM, Hopkins D, Smith D, Pernet A, Hallett W, Reed L, Marsden
PK, Amiel SA: The role of insulin in human brain glucose: an 18fluoro-
deoxyglucose positron emission tomography study. Diabetes 51:3384–
3390, 2002
41. Watson GS, Craft S: Modulation of memory by insulin and glucose:
neuropsychological observations in Alzheimer’s disease. Eur J Pharmacol
490:97–113, 2004
42. Mattson MP, Maudsley S, Martin B: A neural signaling triumvirate that
influences ageing and age-related disease: insulin/IGF-1, BDNF and sero-
tonin. Ageing Res Rev 3:445–464, 2004
43. Hamabe W, Fujita R, Ueda H: Neuronal necrosis inhibition by insulin
through protein kinase C activation. J Pharmacol Exp Ther 307:205–212,
2003
44. Whitesell RR, Ward M, McCall AL, Granner DK, May JM: Coupled glucose
transport and metabolism in cultured neuronal cells: determination of the
rate-limiting step. J Cereb Blood Flow Metab 15:814–826, 1995
45. Huang TJ, Verkhratsky A, Fernyhough P: Insulin enhances mitochondrial
inner membrane potential and increases ATP levels through phosphoino-
sitide 3-K in adult sensory neurons. Mol Cell Neurosci 28:42–54, 2005
46. Henneberg N, Hoyer S: Short-term or long-term intracerebroventricular
(ivc) infusion of insulin exhibits a discrete anabolic effect on cerebral
energy metabolism in the rat. Neurosci Lett 175:153–156, 1994
47. van der Heide LP, Kamal A, Artola A, Gispen WH, Ramakers GMJ: Insulin
modulates hippocampal activity-dependent synaptic plasticity in a N-
methyl-D-aspartate receptor and phosphatidyl-inositol-3-K-dependent
manner. J Neurochem 94:1158–1166, 2005
48. Voll CL, Auer RN: Insulin attenuates ischemic brain damage independent
of its hypoglycemic effect. J Cereb Blood Flow Metab 11:1006–1014, 1991
49. Hamilton MG, Tranmer BI, Auer RN: Insulin reduction of cerebral infarc-
tion due to transient focal ischemia. J Neurosurg 82:262–268, 1995
50. Johan Groeneveld AB, Beishuizen A, Visser FC: Insulin: a wonder drug in
the critically ill? Crit Care 6:102–105, 2002
INSULIN AND NEURONAL ENERGY METABOLISM
2870 DIABETES, VOL. 55, OCTOBER 2006
